Financial Performance - The company's operating revenue for the first half of 2023 was CNY 609,032,829.06, representing a 31.89% increase compared to CNY 461,788,519.84 in the same period last year[21]. - The net profit attributable to shareholders of the listed company was CNY 57,053,385.37, an increase of 11.35% from CNY 51,238,039.16 in the previous year[21]. - The net profit after deducting non-recurring gains and losses was CNY 49,949,859.94, up 11.84% from CNY 44,662,803.52 year-on-year[21]. - The basic earnings per share increased to CNY 0.1117, reflecting a growth of 10.92% compared to CNY 0.1007 in the previous year[21]. - The total assets at the end of the reporting period were CNY 2,597,701,642.40, a slight increase of 0.43% from CNY 2,586,568,848.41 at the end of the previous year[21]. - The company reported a significant decrease in net cash flow from operating activities, which was negative CNY 50,236,281.89, compared to a positive CNY 47,966,453.73 in the same period last year, marking a decline of 204.73%[21]. - The weighted average return on net assets was 3.30%, slightly up from 3.11% in the previous year[21]. - The total net assets attributable to shareholders of the listed company increased to CNY 1,746,936,398.32, reflecting a growth of 1.84% from CNY 1,715,389,713.37 at the end of the previous year[21]. Research and Development - The company is committed to continuous R&D investment to enhance its innovation capabilities and product development[33]. - Research and development expenses surged by 73.54% to ¥14,909,087.27, up from ¥8,591,034.80, indicating a significant increase in R&D projects[49]. - The R&D expenditure for the first half of 2023 was 8.7 million yuan, accounting for approximately 6.2% of total revenue[151]. - The company aims to enhance its research and development efforts to drive innovation and maintain competitive advantage in the market[159]. Market Expansion and Strategy - The company is focusing on expanding its market presence beyond its base in Northwest China, enhancing brand competitiveness through strategic partnerships and marketing activities[37]. - The company is actively participating in major national conferences and events to increase brand awareness and product exposure[37]. - The company plans to enhance R&D capabilities and invest in innovative drug development to strengthen its core competitiveness[69]. - The company plans to continue expanding its market presence and invest in new product development in the upcoming quarters[151]. - The company expects a revenue growth of 10% for the second half of 2023, driven by new product launches and market expansion efforts[151]. Operational Efficiency - The company has implemented the "Amoeba" management model to improve operational efficiency and promote high-quality development[40]. - The company emphasizes the importance of optimizing management practices to adapt to its expanding business scale[71]. - The company aims to enhance its operational efficiency through strategic partnerships and potential acquisitions in the pharmaceutical sector[151]. - The company is adapting its procurement and production strategies to align with market demands and optimize cost efficiency[34]. Financial Health and Assets - The company's cash and cash equivalents decreased significantly to -¥77,572,139.46, a decline of 763.67% from a positive balance of ¥11,688,389.84 last year[49]. - The company's total liabilities increased to CNY 1,200,000,000.00 as of June 30, 2023, compared to CNY 1,000,000,000.00 as of June 30, 2022, indicating a growth of 20.0%[141]. - The total assets of the company at the end of the reporting period amounted to 4,443 million yuan, indicating a stable financial position[157]. - The total liabilities at the end of the reporting period were 1.2 billion yuan, indicating a manageable debt level[152]. Corporate Governance and Compliance - The annual shareholders meeting had a participation rate of 63.00% on April 20, 2023[74]. - There were no changes in the board of directors, supervisors, or senior management during the reporting period[75]. - The company has not engaged in any significant asset or equity sales during the reporting period[59]. - There were no significant lawsuits or arbitration matters during the reporting period[88]. - The company has no non-operating fund occupation by controlling shareholders or related parties[84]. Social Responsibility - The company actively engaged in poverty alleviation efforts, employing nearly 100 local farmers and benefiting over 2,000 households[81]. Risks and Challenges - The company faces risks from industry policy changes, raw material price fluctuations, and talent shortages, with strategies in place to mitigate these risks[66][67][68].

Group 1: Company Acquisition and Control - Gansu Guotou's acquisition of Foci Group is progressing with financial and legal due diligence ongoing [1] - The actual controller remains the Lanzhou Municipal Government's State-owned Assets Supervision and Administration Commission until the acquisition is completed [1] - Future development plans and potential new strategic investors will be clarified after the change of actual controller [1] Group 2: Market Expansion Strategy - The company aims to strengthen its presence in the Northwest market while expanding into East, South, and Southwest China through strategic partnerships [2] - International market expansion will leverage the company's overseas brand and resources, utilizing the Belt and Road Initiative to explore new sales models [2] Group 3: Key Product Development - The company has 467 product approval numbers and produces over 110 varieties, focusing on classic formulas and health products [2] - Major products include Liuwei Dihuang Wan, a proprietary formula for children's health, and other products targeting elderly diseases, aiming for over 100 million in revenue for key items [2] - The company plans to enhance market promotion for its unique products, including Ejiao and An Gong Niu Huang Wan, which are seeing increased market demand [2] Group 4: Strategic Goals and Growth - The company targets a revenue scale of 3 billion by 2025, with two-thirds of growth from internal development and one-third from external expansion [3] - Future acquisitions will focus on high-quality domestic companies that align with the company's strategic development [3] - The company is expanding its granule formula business, having established two subsidiaries for production and sales in Gansu [3] Group 5: Marketing and Personnel - The company currently employs over 400 marketing personnel, with plans to increase staff as it expands into new sales channels [3] - The company emphasizes compliance with information disclosure regulations during investor communications, highlighting the importance of investment risk awareness [3]

Financial Performance - The company's revenue for Q1 2023 was CNY 307,394,758.83, representing a 29.77% increase compared to CNY 236,878,872.61 in the same period last year[5] - Net profit attributable to shareholders was CNY 27,454,528.98, up 27.72% from CNY 21,496,460.61 year-on-year[5] - The net profit after deducting non-recurring gains and losses was CNY 23,201,984.94, reflecting a 29.17% increase from CNY 17,962,206.37 in the previous year[5] - Total operating revenue for Q1 2023 reached CNY 307,394,758.83, a 29.7% increase from CNY 236,878,872.61 in the same period last year[22] - Net profit for Q1 2023 was CNY 27,436,028.66, representing a 27.5% increase compared to CNY 21,545,308.08 in Q1 2022[23] - The total comprehensive income attributable to the parent company was CNY 27,454,528.98, compared to CNY 21,496,460.61 in the previous period, representing an increase of approximately 27.9%[24] Assets and Liabilities - The company's total assets increased by 4.67% to CNY 2,707,397,143.84 from CNY 2,586,568,848.41 at the end of the previous year[5] - Total liabilities increased to CNY 945,487,854.39, up from CNY 852,595,587.62 year-on-year[20] - The equity attributable to shareholders of the parent company rose to CNY 1,742,844,242.35, compared to CNY 1,715,389,713.37 in the previous year[20] - The company reported a total current asset of 1,416,547,234.24 RMB, an increase from 1,291,068,156.43 RMB at the beginning of the year, representing an increase of approximately 9.8%[18] Cash Flow - The net cash flow from operating activities was negative at CNY -6,151,682.38, a decrease of 122.99% compared to CNY 26,757,794.43 in the same period last year[8] - Cash inflow from operating activities totaled CNY 281,429,158.62, up from CNY 198,038,162.63, marking a rise of about 42.0%[26] - Cash outflow from operating activities was CNY 287,580,841.00, compared to CNY 171,280,368.20 in the previous period, resulting in a net cash flow from operating activities of -CNY 6,151,682.38[26] - Investment activities resulted in a cash outflow of CNY 15,583,185.26, significantly higher than CNY 1,395,928.90 in the previous period, leading to a net cash flow from investment activities of -CNY 13,583,185.26[27] - Cash inflow from financing activities was CNY 500,000.00, while cash outflow was CNY 14,049,700.00, resulting in a net cash flow from financing activities of -CNY 13,549,700.00[27] - The ending balance of cash and cash equivalents decreased to CNY 354,400,479.61 from CNY 384,067,722.30, a decline of approximately 7.7%[27] Shareholder Information - The total number of common shareholders at the end of the reporting period is 31,467[11] - The largest shareholder, Lanzhou Foci Pharmaceutical Industry Development Group, holds 61.63% of the shares, totaling 314,713,676 shares, with 150,000,000 shares pledged[11] - The company reported that the pledge of shares by the controlling shareholder accounts for 29.37% of the total share capital[13] Research and Development - Research and development expenses increased by 56.47% to CNY 6,296,817.19, up from CNY 4,024,334.17 year-on-year, indicating a focus on enhancing research collaboration[7] - Research and development expenses increased to CNY 6,296,817.19, up 56.5% from CNY 4,024,334.17 in the previous year[22] - The company plans to continue focusing on R&D and market expansion strategies to drive future growth[22] Management and Operational Costs - The company's management expenses rose by 59.44% to CNY 20,733,888.20, attributed to increased depreciation costs[7] - Total operating costs amounted to CNY 281,431,478.22, up 33% from CNY 211,498,791.15 year-on-year[22] Changes in Control - The controlling shareholder, Lanzhou Foci Pharmaceutical Industry Development Group, is undergoing a change in actual control, with Gansu State-owned Assets Investment Group intending to acquire 100% of its equity[14] - Gansu State-owned Assets Investment Group will indirectly hold 61.63% of the company's issued shares post-acquisition, triggering a mandatory tender offer for the remaining shares[15] - The tender offer price is set at 9.60 RMB per share, covering 195,943,324 shares, which is 38.37% of the company's issued shares[15] - The company is actively progressing with the necessary audits and approvals for the change in control, which carries certain uncertainties[16] Other Information - The company reported a government subsidy of CNY 5,059,784.65, contributing to its non-recurring gains[6] - The company reported an investment income of CNY 612,806.12, indicating a positive contribution from investments[23] - The company did not undergo an audit for the first quarter report[28] - The report was presented by the board of directors on April 25, 2023[29]

证券代码：002644 证券简称：佛慈制药 佛慈制药投资者关系活动记录表 编号：20230412 | | □特定对象调研 □分析师会议 | | --- | --- | | 投资者关系 | □媒体采访 √业绩说明会 | | 活动类别 | □新闻发布会 □路演活动 | | | □现场参观 □其他 | | 参与单位名称 及人员名称 | 参与公司 2022 年度业绩说明会的投资者 | | 时间 2023 | 年 月 日 4 12 15:00—17:00 | | 地点 | 全景网"投资者关系互动平台"（https://ir.p5w.net/zj） | | 形式 | □现场 √ 网上 □电话会议 | | 公司接待 | 董事长石爱国先生，董事、副总经理王迎春先生，独立董事龙 | | 人员姓名 | 凤鸣女士，董事会秘书王军辉先生，财务总监岳金风女士。 | | | 公司在全景网"投资者关系互动平台"采用网络远程的方 | | | 式举行了 2022 年度业绩说明会，公司相关人员与参会投资者 | | | 进行了充分的沟通交流，主要交流问题及回复如下： | | | 1. 公司当时说加班加点生产抗病毒药，一季度什么情况？ | | | ...

证券代码：002644 证券简称：佛慈制药 公告编号：2023-014 兰州佛慈制药股份有限公司 关于举行 2022 年度业绩说明会的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 兰州佛慈制药股份有限公司（以下简称"公司"）已于 2023 年 3 月 31 日披露 了《2022 年年度报告》。为便于广大投资者更深入全面地了解公司 2022 年年度 报告和经营情况，公司将于 2023 年 4 月 12 日（星期三）15:00—17:00 在全景网 举办 2022 年度业绩说明会。本次年度业绩说明会将采用网络远程的方式举行， 投资者可登陆全景网"投资者关系互动平台"（https://ir.p5w.net/zj）参与本次年度 业绩说明会。 出席本次说明会的人员有：公司董事长石爱国先生，董事、副总经理王迎春 先生，独立董事龙凤鸣女士，董事会秘书王军辉先生，财务总监岳金风女士。 为充分尊重投资者、提升交流的针对性，现就公司 2022 年度业绩说明会提 前向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可于 2023 年 4 月 11 日（星期二）12：0 ...

Dividend Distribution - The company plans to distribute a cash dividend of 0.5 RMB per 10 shares to all shareholders, based on a total of 510,657,000 shares[4]. - The board of directors has approved the profit distribution plan, which does not include any bonus shares or capital reserve transfers[4]. - The company’s cash dividend policy was executed in accordance with its articles of association, ensuring the protection of minority shareholders' rights[144]. Financial Performance - The company's operating revenue for 2022 was ¥1,019,176,339.15, representing a 24.65% increase compared to ¥817,640,826.02 in 2021[6]. - The net profit attributable to shareholders for 2022 was ¥105,945,825.56, a 13.60% increase from ¥93,258,956.07 in 2021[6]. - The net cash flow from operating activities surged by 510.48% to ¥72,369,956.27 in 2022, compared to ¥11,854,642.44 in 2021[6]. - The basic earnings per share for 2022 was ¥0.2075, up 13.64% from ¥0.1826 in 2021[6]. - Total assets at the end of 2022 reached ¥2,586,568,848.41, a 9.97% increase from ¥2,352,093,709.48 at the end of 2021[6]. - The net assets attributable to shareholders increased by 6.24% to ¥1,715,389,713.37 at the end of 2022, compared to ¥1,614,577,062.37 at the end of 2021[6]. - The company reported a significant increase in government subsidies, totaling ¥75,662,519.83 in 2022, compared to ¥32,638,552.20 in 2021[8]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion CNY in 2022, representing a year-on-year growth of 15%[119]. Market Position and Strategy - The company is positioned in a growing market driven by national policy support and increasing health awareness, indicating a favorable outlook for the traditional Chinese medicine sector[30]. - The company faces intensified competition and regulatory scrutiny in the pharmaceutical industry, which may impact its market positioning[32]. - The company is focusing on high-quality development in the traditional Chinese medicine sector, aligning with national strategic initiatives[31]. - The company is actively pursuing international market expansion and has acquired Hong Kong Fozi Pharmaceutical Co., Ltd. to strengthen its overseas presence[39]. - The company aims to create over 1 billion market segments in regions such as Shanghai, Jiangsu, Zhejiang, Guangdong, and Sichuan-Chongqing, as well as international markets[85]. - The company is expanding into five major markets, including consolidating its base in Shaanxi and Gansu, and developing the North China market with strategic partners[86]. Research and Development - The company is focused on innovation-driven development, increasing R&D investment to enhance its core competitiveness in traditional Chinese medicine[35]. - R&D investment amounted to ¥23,555,522.20 in 2022, an increase of 21.69% compared to ¥19,357,135.92 in 2021[66]. - The number of R&D personnel increased to 189 in 2022, up 15.24% from 164 in 2021, with a proportion of 15.99% of total employees[67]. - New product development initiatives are underway, with an investment of 100 million CNY allocated for R&D in traditional Chinese medicine[119]. - The company is actively developing new products and enhancing its R&D capabilities through collaboration with research institutions[65]. Corporate Governance - The company emphasizes the importance of a modern corporate governance structure to ensure compliance with regulations and enhance operational transparency[101]. - The board of directors operates under a structured governance framework, including specialized committees for strategy, audit, compensation, and nomination[105]. - The company has established an audit committee to oversee internal and external audits, ensuring compliance and accuracy of financial information[105]. - The company has maintained a stable operational structure despite the changes in leadership, indicating a focus on continuity in its strategic direction[113]. - The company has a performance-based remuneration system for its directors and senior management[128]. Social Responsibility - The company actively engages in social responsibility initiatives, including poverty alleviation and community health lectures[161]. - The company donated medical supplies and materials worth 12 million yuan to various medical institutions and schools through the Red Cross Society[160]. - The company has implemented a change in accounting estimates for bad debt provisions, reducing the expected credit loss rate for non-overdue receivables from 2.59% to 0%[167]. - The company has strengthened its environmental responsibility awareness and is committed to building a green factory[160]. Internal Control and Compliance - The company has established 250 management systems, with 82 new or revised systems during the reporting period, enhancing internal control measures[146]. - The company reported no significant internal control deficiencies during the reporting period[147]. - The company maintained effective internal control over financial reporting as of December 31, 2022, according to the internal control audit report[149]. - The internal control audit report received a standard unqualified opinion, indicating no major deficiencies[150]. Employee Management - The total number of employees at the end of the reporting period was 1,404, including 1,096 at the parent company and 308 at major subsidiaries[139]. - The company has a training center that focuses on improving employees' professional skills and overall quality through various training programs[141]. - The company has maintained a harmonious labor relationship by ensuring employee rights and providing welfare benefits[156]. Financial Audits and Reporting - The audit firm Lianda CPA was appointed for the 2022 financial audit, with a fee of 390,000 RMB, marking the first year of service[171]. - The company conducted regular communications with the annual audit firm regarding the audit of the previous year's financial statements[136]. - The board of directors held a total of 7 meetings during the reporting period, with decisions disclosed on various dates[131].

证券代码：002644 证券简称：佛慈制药 佛慈制药投资者关系活动记录表 编号：20140710 | --- | --- | --- | |---------------------|------------------------------|--------------------------------------------------| | | ■ 特定对象调研 | □分析师会议 | | | □ 媒体采访 | □业绩说明会 | | 投资者关系活动 类别 | □ 新闻发布会 | □路演活动 | | | □ 现场参观 | | | | □ 其他 | （请文字说明其他活动内容） | | 参与单位名称及 | 宏源证券研究所：赵佳、王晓锋 | | | 人员名称 | | | | 时间 | 2014 年 7 月 10 | 日 下午 15：00——16：00 | | 地点 | 公司三楼会议室 | | | 上市公司接待 | | | | 人员姓名 | 董事长：李云鹏 | 证券部：李莹 | | 投资者关系活动 | | 此次调研活动以会谈交流形式进行，主要内容如下： | | 主要内容介绍 | | 1、问：政府对公司搬入新区的 ...